
The global breath analyzers market size is calculated at US$ 1.022 billion in 2024, grew to US$ 1.2 billion in 2025, and is projected to reach around US$ 5.12 billion by 2034. The market is expanding at a CAGR of 17.44% between 2025 and 2034.
Increasing Personal Use: Due to growing awareness, there is a rise in the use of breath analyzers. This, in turn, is increasing their adoption by the consumers to avoid the risk of alcohol related accidents. Moreover, their availability on online platforms is increasing their adoption rates.
Growing Research and Development: There is an increase in the research and development of breath analyzers for enhancing applications. This, in turn, is leading to new collaborations among the industries as well as institutes. They are focusing on improving their accuracy and specificity, as well as innovations for the early detection of different diseases.
For instance,
The R&D of breath analyzers focuses on enhancing their accuracy, portability, sensitivity, and versatility to increase their applications, along with growing advancements in sensor technologies.
Key Players: Intoximeters, Drägerwerk, Inc., BACtrack, Lifeloc Technologies
The clinical trials and regulatory approval of the breath analyzers focus on the detection of risk levels for medical diagnostics.
Key Players: Lifeloc Technologies, Drägerwerk, Inc., Lion Laboratories, Intoximeters
The packaging and serialization of breath analyzers include packaging that protects their integrity, mouthpiece sterile materials, and a unique device identification (UDI) system for their regulatory traceability.
Key Players: DuPont de Nemours Inc., Berry Global, Amcor Plc, Oliver Healthcare Packaging, CCL Healthcare
User instructions, test preparation and interpretation information, and technical support are provided in the patient support and services of the breath analyzer.
Key Players: BACtrack, Lifeloc Technologies, FoodMarble Digestive Health Ltd., Drägerwerk
In April 2025, after announcing the non-exclusive distribution agreement between Cannabix Technologies Inc. and Alco Prevention Canada, the CEO of Cannabix Technologies, Rav Mlait, stated that truly innovative new technologies are being supplied to the marketplace for breath testing by Cannabix. New opportunities for the development of disruptive and innovative technologies are being provided by the growing breath testing for marijuana and alcohol segment, which will be the main focus of Cannabix, aiming to achieve new milestones in 2025.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com